Evaluation of Biomarker Levels in Gingival Crevicular Fluid of Patients With Different Periodontal Diseases
Evaluation of Peptidyl Arginine Deiminase 4 (PAD4), Galectin-3 and TNF-α Levels in Gingival Crevicular Fluid of Patients With Different Periodontal Diseases
1 other identifier
interventional
60
1 country
1
Brief Summary
Objectives: The aim of this study is; detection of peptidyl arginine deiminase4 (PAD4), galectin-3 and tumor necrosis factor alpha (TNF-α) levels in gingival crevicular fluid (GCF) samples of periodontally healthy, gingivitis and periodontitis patients and the possible correlation between these values and clinical parameters of periodontal diseases. Materials and methods: Samples of GCF were obtained from 60systemically healthy non-smoker individuals with periodontitis (P, n=20), gingivitis(G, n=20) and healthy periodontium (S, n=20). Full-mouth clinical periodontal measurements including probing depth (PD), clinical attachment level (CAL), bleeding on probing (BOP), gingival index (GI) and plaque index (PI) were also recorded. Enzyme-linked immunosorbent assay (ELISA) was used to determine PAD4, galectin-3 and TNF-α levels in the biological samples.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Apr 2019
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 25, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
September 25, 2019
CompletedFirst Submitted
Initial submission to the registry
February 27, 2021
CompletedFirst Posted
Study publicly available on registry
March 2, 2021
CompletedMarch 2, 2021
March 1, 2021
6 months
February 27, 2021
March 1, 2021
Conditions
Outcome Measures
Primary Outcomes (2)
The total amount of Galectin-3 in GCF
The total amount of Galectin-3 in GCF
24 hours after taking the clinical measurements at the first visit
The total amount of PAD4 in GCF
The total amount of PAD4 in GCF
24 hours after taking the clinical measurements at the first visit
Secondary Outcomes (1)
The total amount of TNF-α in GCF
24 hours after taking the clinical measurements at the first visit
Study Arms (3)
Healthy Periodontium
EXPERIMENTALFull-mouth clinical periodontal measurements recorded and GCF obtained.
Gingivitis
EXPERIMENTALFull-mouth clinical periodontal measurements recorded and GCF obtained.
Periodontitis
EXPERIMENTALFull-mouth clinical periodontal measurements recorded and GCF obtained.
Interventions
4 samples of gingival crevicular fluid, 1 from each quadrant of the patient's jaw, were collected by means of paper strips.
Eligibility Criteria
You may qualify if:
- Systemically healthy (The determination of healthy volunteers will be based on the statements of the patients in the anamnesis. No additional examinations will be made.)
- At least twenty permanent teeth in the mouth
- Non-smoker
- No medication for continuous use
- Those who have not used antibiotics, anti-inflammatory and systemic corticosteroid drugs in the last 6 months.
- Not in pregnancy or lactation period.
- For the periodontitis group that has not received periodontal treatment in the last 6 months
- For the periodontitis group; According to the evaluation made in 6 regions of each tooth, individuals with 30% or more bleeding on probing area, at least 2 teeth not adjacent to each quarter jaw with a depth of 5 mm or more and 4 mm or more attachment loss, coronal 1/3 and more on radiography (horizontal and / or vertical) bone loss
- For the gingivitis group; According to the evaluation made in 6 regions of each tooth, individuals with 10% or more bleeding on probing area, having a probing depth of less than 4mm and no attachment loss
- For healthy group; According to the evaluation made in 6 regions of each tooth,individuals with less than 10% bleeding on probing area, having a probing depth less than 4mm and no loss of attachment were included in the study.
You may not qualify if:
- Any oral or systemic disease
- Regularly using a systemic medication
- During pregnancy or lactation
- Received periodontal treatment within the last 6 months.
- Those who received antibiotic, anti-inflammatory or systemic corticosteroid medication in the last 6 months
- Smokers are not included in the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Izmir Katip Çelebi University Department of Periodontology
Izmir, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Mehmet Sağlam
Izmir Katip Çelebi University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Research Assistant
Study Record Dates
First Submitted
February 27, 2021
First Posted
March 2, 2021
Study Start
April 1, 2019
Primary Completion
September 25, 2019
Study Completion
September 25, 2019
Last Updated
March 2, 2021
Record last verified: 2021-03
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF